microbiological pipette in the genetic laboratory
Our Work

Latham Represents MedAlliance in Its Acquisition by Cordis

October 26, 2022
Multidisciplinary team advises medical tech company in the US$1.135 billion transaction.

Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of US$35 million, upfront closing payment of US$200 million, regulatory achievement milestones of up to US$125 million, and commercial milestones of up to US$775 million through 2029 for total consideration of up to US$1.135 billion.

Latham & Watkins LLP represents MedAlliance in the transaction with a corporate deal team led by Boston partner Hans Brigham and Boston associate Laki Triantafylidis. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Boston associate Jeremiah Cowen; on benefits and compensation matters by Boston partner Josh Friedman, with Chicago associate Dan Gocek; on intellectual property and data privacy matters by Boston partner Sarah Gagan, with New York associate Arun Mohan, London associate Calum Docherty, and Boston associate Kiara Vaughn; on US regulatory matters by Washington, D.C. partner Ben Haas and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings; on EU regulatory matters by Paris/Brussels partner Eveline Van Keymeulen, with London associate Ranulf Barman; and on antitrust matters by Brussels counsel Wesley Lepla and Philipp Studt and Washington, D.C. counsel Patrick English.